Shares of Pharming Group (NASDAQ:PHAR – Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $8.30, but opened at $8.68. Pharming Group shares last traded at $8.70, with a volume of 971 shares.
Analysts Set New Price Targets
PHAR has been the subject of a number of recent analyst reports. Oppenheimer lowered their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a report on Thursday.
Check Out Our Latest Research Report on Pharming Group
Pharming Group Stock Down 1.6 %
Pharming Group (NASDAQ:PHAR – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The firm had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. During the same quarter last year, the company posted $0.02 earnings per share. On average, sell-side analysts anticipate that Pharming Group will post -0.15 earnings per share for the current year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in shares of Pharming Group (NASDAQ:PHAR – Free Report) by 75.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,110 shares of the company’s stock after buying an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 as of its most recent filing with the Securities and Exchange Commission. 0.03% of the stock is owned by institutional investors and hedge funds.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
- Five stocks we like better than Pharming Group
- How to Find Undervalued Stocks
- Inflation Risk Rising, Key Trades Investors Are Making Now
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Oil Stocks to Watch Before Earnings Come Out
- Pros And Cons Of Monthly Dividend Stocks
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.